Track 2: Tecnologías para la transformación del sistema sanitario 2.1. Las tecnologias en medicina personalizada

1. Technologies in
Personalized Medicine
Luis Carlos Campo
GE Healthcare
May 24th, 2012

2. “ The doctor of
the future will
give no medicine
but will interest
his patients in the
care of the
human frame, in
diet and in the
cause and
prevention of
disease .”

3. Early stage: PREVENTION Early stage: BLUEPRINT
+

4. Oncology: 2.9M case diagnose / year
Response to therapy: 25%

5. If we’re all different….
We can´t content with «one size fits all»

6. Current response to therapies
% who respond
Category of Disease
to therapy
Deterioration of
Analgesics for pain 80%
patient’s quality
Asthma 60% of life
Cardiac Arrythmias 60%
Schizophrenia 60%
Migraine (acute) 52%
Migraine (prophylaxis) 50%
Increase cost of
Rheumatoid Arthritis 50%
healthcare
Osteoporosis 48%
HCV 47%
Alzheimer’s Disease 30%
Oncology 25%
*Source:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Dr
ugInteractionsLabeling/ucm114848.htm

7. Pharma’s transition to bio-therapeutics
Opportunity growing for bio-therapeutics Pharma business model is changing
Pharma annual sales trend Medium efficiency
Traditional
Bio-therapeutics
Pharmaceuticals
Sales ▼ $17B Sales ▲ $23B
Pharma M&A to access High efficiency
bio-therapeutics content
2009 Roche Targeted
patient,
Genentech Molecular diagnostics
personalized
treatment
2009 Amgen Immunex
2008 AstraZeneca
Precise molecular diagnostics needed
Medimmune
to pinpoint patients who will respond
2008 Takeda Millenium
2008 Lilly

8. Personalized medicine
In Vivo[18F]AH110690 PET Imaging
90 – 120 min summation
In Vitro
One
size fits
all The + Alzheimer’s Disease Age matched control
right treatment Complete
for the Diagnostic
right person Solution
Targeted drugs need powerful diagnostics

9. Who are we? What do we do?

10. General Electric (GE) today
GE Energy – 30% GE Healthcare – 18% GE Capital – 30%
GE Transportation – 3% GE Aviation – 13% GE Home & Business –
6%
Power&
$12.6B earnings
Water
A conglomerate of very diverse businesses $14.7B cash flow

11. $17B broad technology portfolio
Diagnostic & Clinical Information
Molecular Medicine
Equipment technologies & Service
~ 10% revenue
~ 46% revenue ~ 34% revenue
Diagnostic Electronic Bio
Imaging Medical Process
Records
(EMR)
Protein &
Clinical Picture cell science
Products Archiving
(PACS)
Contrast
Media
Clinical &
Home
Service Molecular
Health
Solutions Diagnóstics

12. Global Healthcare challenges

13. Global Healthcare challenges
Populations aging …and demand is growing
• 2030: the number of people over • Global number of Alzheimer’s patients
65 will will grow from 36 million in 2009 to 66
− Increase 140% in developing million in 2030 and 115 million in 2050
world • Global number of cancer patients is
− Increase 51% in developed predicted to grow from 10.1 million in
world 2000 to 15.7 million in 2020
• 48.6% relative lifetime healthcare • US: chronic disease up 80% and
expenditure is expended after age 65 spending up 260% over last 20 years.
Spend to increase 2.5X by 2023
8.0 Healthcare spend (%)
7.4
6.5 GDP (%)
4.6 4.2
3.4 2.2
3.9 4.2 3.5 3.3 1.6
2.0 2.2 1.4 1.5
1.2 1.2
KOR POL TUR GBR OECD USA MEX JPN DEU
2000-08
Healthcare expenditure outpacing GDP growth

14. Statistical data: age of population in Spain
in 2000 in 2050
SPAIN
MEN WOMEN
85+
80 - 84
75 - 79
70 - 74
65 - 69
60 - 64
55 - 59
50 - 54
45 - 49
40 - 44
35 - 39
30 - 34
25 - 29
20 - 24
15 - 19
10 - 14
5-9
0-4
,10 ,8 ,6 ,4 ,2 ,0 ,0 ,2 ,4 ,6 ,8 ,10
> 65 years: from 17% in 2000 to 36% in 2050

15. What’s GE Healthcare doing?

16. GE strategy addresses trends in healthcare
Innovation that is Broader products portfolio and
1 clinically and in-country-for-country (ICFC)
economically relevant products
Technologies and solutions to
2 The industralization of
healthcare
help hospitals work better and
reduce variability
Investing in game changing
The digitalization of
3 healthcare
Healthcare IT (HCIT)
technologies
Molecular diagnostics to detect
Diagnostics and disease & match the right drug.
4 therapy moving to Life sciences tools to enable
the next generation of bio-
molecular level
therapeutics

17. GE HC – Enables Personalized Medicine
The way we look at disease is Assembling the necessary
changing technologies to lead
Imaging Molecular imaging
Molecular Diagnostics
Mammography Molecular Biopsy Tools In-Vivo Diagnostics
Tumor IHC Stain
+ +
Gene
Molecular pathology
sequencing
Responders
In-Vitro Diagnostics
Precise therapy
Toxic No requires precise
impact impact
diagnostics +
Patient populations

18. CLARIENT: pathology test services
Entry to the market via services
Clarient acquired Dec 2010
~ 450 employees, 300 tests for Cancer Diagnostics
Great reputation, customer base of >2,000 pathologists in the US
Ongoing globalization using GEHC infrastructure
Introduction of proprietary innovative technology for pathology
Generit Genetic Protein Cell
Fingerprint messages Expression Function

19. Digital Pathology
High throughput with slide digitalization
From glass To digital
Digitize, annotate
Stain A Her 2
Stain B
p53
Share
Stain C
Ki67
Digitalization improves capacity; enables quick
and accurate share of information

20. Alzheimer’s Disease
… an unmet need for complete Dx solution
Enabling First Generation of Disease Modifying Drugs
The imaging agents described are not approved for use by the FDA or any other health regulatory agency

21. Radiology & Pathology: enablers of
personalized medicine
Early detection Complete patient diagnostics Personalized therapy
GP Radiologist Pathologist Oncologist
Image-
guided
biopsies
Biopsy Treatment decision
Screening Imaging
analysis and monitoring
Suspicion of cancer, more tests needed Definitive diagnostic… tissue-based today
Radiology imaging for mass
Advanced diagnostic… activity, molecular
confirmation, location
Therapy selection limited Enables specific therapy selection

22. Becoming the leader in diagnostics focused
on personalized medicine
Diagnostic Biomarker
equipment In vivo development
Personalized
medicine: multiple
Right drug to
Right drug to the
the right components
patient
right patient
GE Healthcare
makes it happen today !
Biopsy Digital
In vitro pathology
analysis

23. Thank you !!